- Trials with a EudraCT protocol (415)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
415 result(s) found for: Endocrine Tumor.
Displaying page 1 of 21.
EudraCT Number: 2016-002240-17 | Sponsor Protocol Number: ATR-101-301 | Start Date*: 2017-05-16 | |||||||||||
Sponsor Name:Millendo Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing’s Syndrome | |||||||||||||
Medical condition: endogenous Cushing’s syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002610-19 | Sponsor Protocol Number: P040303 | Start Date*: 2007-07-06 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Dota-Toc-(68Ga) dans les tumeurs endocrines digestives. Intérêt de l'imagerie TEP-TDM. | |||||||||||||
Medical condition: Endocrine neoplasm | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003936-21 | Sponsor Protocol Number: TD-212-2308 | Start Date*: 2015-09-14 | ||||||||||||||||||||||||||
Sponsor Name:Hôpital de Jolimont | ||||||||||||||||||||||||||||
Full Title: A PROSPECTIVE MULTICENTRIC, PROOF OF CONCEPT STUDY TO EVALUATE THE VALUE OF 18-FDG-PET-SCAN ON TUMOUR RESPONSE IN PATIENTS WITH A PROGRESSIVE PANCREATIC ENDOCRINE TUMOUR RECEIVING A COMBINATION THE... | ||||||||||||||||||||||||||||
Medical condition: Progressive well or moderately differentiated neuroendocrine tumour of the pancreas | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004362-26 | Sponsor Protocol Number: I3Y-MC-JPCF | Start Date*: 2017-08-14 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High-Risk, Node-Positive, ... | |||||||||||||
Medical condition: Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) HU (Ongoing) GB (GB - no longer in EU/EEA) BE (Ongoing) DK (Trial now transitioned) FI (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) CZ (Ongoing) FR (Ongoing) PT (Trial now transitioned) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007348-32 | Sponsor Protocol Number: CSOM230D2203 | Start Date*: 2009-05-06 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin | |||||||||||||
Medical condition: The following tumors are included: 1. NETs of the pancreas or duodenum: Insulinoma, Gastrinoma, VIPoma, glucagonoma, 2. Pituitary NETs: Thyrotropic-pituitary adenoma (TSH), Gonadotropic adenoma, Pr... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000494-20 | Sponsor Protocol Number: ABC-SE | Start Date*: 2016-07-03 | |||||||||||
Sponsor Name:Skåne University Hospital, Department of Oncology | |||||||||||||
Full Title: A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Based Treatment with Focus on Mechanisms of Resistance to Endocrine Based Treatment (fulvestrant/aroma... | |||||||||||||
Medical condition: Estrogen receptor positive metastatic or locally advanced inoperable breast cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005181-30 | Sponsor Protocol Number: AFT-05/ABCSG-42/BIG_14-03 | Start Date*: 2015-07-09 | |||||||||||
Sponsor Name:ABCSG GmbH | |||||||||||||
Full Title: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor... | |||||||||||||
Medical condition: To determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) ES (Ongoing) IE (Ongoing) HU (Ongoing) PT (Ongoing) DE (Ongoing) SE (Ongoing) NL (Ongoing) BE (Ongoing) PL (Ongoing) GB (GB - no longer in EU/EEA) IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002312-13 | Sponsor Protocol Number: AK2017-1 | Start Date*: 2017-08-25 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Rigshospitalet | ||||||||||||||||||||||||||||||||||||||
Full Title: PET/CT imaging of uPAR-expression in patients with neuroendocrine tumors using 68Ga-NOTA-AE105 | ||||||||||||||||||||||||||||||||||||||
Medical condition: Patients with neuroendocrine tumors (gastro-entero-pancreatic and bronchopulmonary) | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: DK (Ongoing) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-002512-14 | Sponsor Protocol Number: AK2017-2 | Start Date*: 2017-09-04 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Rigshospitalet | ||||||||||||||||||||||||||||||||||||||
Full Title: PET/CT imaging of angiogenesis in patients with neuroendocrine tumors using 68Ga-NODAGA-E[c(RGDyK)]2 | ||||||||||||||||||||||||||||||||||||||
Medical condition: Patients with neuroendocrine tumors (gastro-entero-pancreatic and bronchopulmonary) | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000425-45 | Sponsor Protocol Number: | Start Date*: 2012-07-03 | |||||||||||||||||||||
Sponsor Name: | |||||||||||||||||||||||
Full Title: Effects of morning vs evening dosing on the pharmacokinetics and pharmacodynamics of sunitinib. | |||||||||||||||||||||||
Medical condition: Renal Cell Cancer, GIST, pancreatic neuroendocrine tumor | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023183-40 | Sponsor Protocol Number: CSOM230I2201 | Start Date*: 2011-06-28 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, open-label phase II multicenter study evaluating the efficacy of oral Everolimus alone or in combination with Pasireotide LAR i.m. in advanced progressive pancreatic neuroendocrine tu... | |||||||||||||
Medical condition: advanced progressive pancreatic neuroendocrine tumors (PNET) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) BE (Completed) DK (Prematurely Ended) DE (Completed) HU (Completed) ES (Completed) NL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005919-30 | Sponsor Protocol Number: AK_NEN_DOTA-FDG_21 | Start Date*: 2022-09-21 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients with Neuroendocrine Neoplasms | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Neuroendocrine neoplasms | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DK (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000888-41 | Sponsor Protocol Number: MetNET1trial | Start Date*: 2014-06-05 | ||||||||||||||||
Sponsor Name:Fondazione IRCCS Istituto Nazionale dei tumori | ||||||||||||||||||
Full Title: Activity and safety of Everolimus in combination with octreotide LAR and Metformin in patients with advanced pancreatic well-differentiated Neuroendocrine Tumors (pWDNETs): a Phase II, open, mono... | ||||||||||||||||||
Medical condition: advanced/ or not resectable well differnciated pancreatic neuroendocrin tumor | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003553-19 | Sponsor Protocol Number: IBCSG59-19/BIG18-02 | Start Date*: 2019-06-25 | ||||||||||||||||
Sponsor Name:International Breat Cancer Study Group (IBCSG) | ||||||||||||||||||
Full Title: A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2... | ||||||||||||||||||
Medical condition: patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) FR (Trial now transitioned) HU (Trial now transitioned) AT (Trial now transitioned) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002877-30 | Sponsor Protocol Number: CSOM230B2212 | Start Date*: 2006-12-22 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: An open label, multicenter, pilot phase II study of SOM230 s.c. in patients with duodeno-pancreatic (neuro) endocrine tumors and different pituitary diseases (Nelsonメs syndrome, non-functioning ad... | |||||||||||||
Medical condition: duodeno-pancreatic (neuro) endocrine tumors and different pituitary diseases (Nelsonメs syndrome, non-functioning adenoma, TSH-adenoma,Gonadotroph adenoma, and PRL-adenoma) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006819-75 | Sponsor Protocol Number: CRAD001C2324 | Start Date*: 2007-10-03 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized double-blind phase III study of RAD001 10 mg/d plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine t... | |||||||||||||
Medical condition: Pancreatic neuroendocrine tumors (also called pancreatic endocrine tumors or islet cell tumors (ICT)) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) IT (Completed) DE (Completed) ES (Completed) FR (Completed) GR (Completed) BE (Completed) GB (Completed) SK (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002196-34 | Sponsor Protocol Number: Neo.Lu.Pa.NET | Start Date*: 2019-11-07 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: A Prospective Phase II Single-Arm Trial on Neoadjuvant Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE Followed by Surgery for resectable Pancreatic Neuroendocrine Tumors (Neo.Lu.Pa.NET) | |||||||||||||
Medical condition: Resectable pancreatic neuroendocrine tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-004019-36 | Sponsor Protocol Number: Protocol 2-55-52030-729 | Start Date*: 2008-12-01 | |||||||||||
Sponsor Name:IPSEN Research and Development, BEAUFOUR IPSEN PHARMA | |||||||||||||
Full Title: Open label extension study of lanreotide Autogel 120 mg in patients with non functioning entero-pancreatic endocrine tumour. | |||||||||||||
Medical condition: Non functioning entero-pancreatic tumour | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) CZ (Completed) SK (Completed) BE (Completed) ES (Completed) PL (Completed) GB (Completed) SE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003927-12 | Sponsor Protocol Number: CHUBX2012/28 | Start Date*: 2014-03-03 | |||||||||||
Sponsor Name:CHU de Bordeaux | |||||||||||||
Full Title: Development of an innovative Gallium 68 radiolabeling of DOTATOC (68Ga-DOTATOC) for PET-CT imaging of neuro-endocrine tumors and preliminary clinical evaluation | |||||||||||||
Medical condition: neuroendocrine tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002781-48 | Sponsor Protocol Number: MedOPP068 | Start Date*: 2019-02-08 | |||||||||||
Sponsor Name:Medica Scientia Innovation Research (MedSIR) | |||||||||||||
Full Title: INTERNATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CONTINUATION OF PALBOCICLIB IN COMBINATION WITH SECOND-LINE ENDOCRINE THERAPY IN H... | |||||||||||||
Medical condition: Hormone receptor-positive/HER2-negative Advanced Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) DE (Completed) SI (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.